Lung protection of cyclopofol in cardiopulmonary bypass surgery

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068516

Enrollment

Unknown

Registered

2023-02-22

Start date

2023-02-22

Completion date

Unknown

Last updated

2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart disease

Interventions

Propofol group:N/A

Cyclopol group:N/A

Sevoflurane group:N/A

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective heart valve replacement under CPB for the first time, NYHA ?-? grades, regardless of gender, age 25-70 years old, weight 45-80 kg; no serious cardiopulmonary function abnormalities, blood pressure, blood sugar in the normal range, no coagulation abnormalities, No history of taking antioxidants, hormonal drugs, and severe immune system diseases; no respiratory tract infection and severe allergic reactions in the recent surgery.

Exclusion criteria

Exclusion criteria: Patients or family members are opposed to drawing blood samples; emergency surgery; patients with serious infectious diseases such as viral hepatitis, tuberculosis and syphilis (to prevent contamination of instruments, etc.); patients with severe cardiac insufficiency or some special reasons that significantly prolong the operation time patient.

Design outcomes

Primary

Measure	Time frame
Respiratory index;Chest lung compliance;Dynamic lung compliance;Superoxide dismutase;Neutrophil elastase;	—

Countries

China

Contacts

Public ContactLiu Shujuan

Peking University Shenzhen Hospital

liusj69@126.com+86 138 2371 2925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026